We combined the novel anti‐LRP6 agent with a well‐known inhibitor against the soluble antagonist DKK1, anti‐DKK1, to demonstrate whether this novel combination strategy provides greater protection against bone loss in the context of MM compared to single treatment approaches. Here, LRP6 is linked to Miyoshi myopathy.